Related Experiment Video

Updated: Jul 9, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Transcriptomics analyses reveal the effects of Pentagamaboronon-0-ol on PI3K/Akt and cell cycle of HER2+ breast

Adam Hermawan1,2,3, Febri Wulandari2, Rohmad Yudi Utomo2,4

  • 1Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281, Yogyakarta, Indonesia.

Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society
|November 29, 2023
PubMed
Abstract

Insights

A curcumin analog, PGB-0-ol, shows cytotoxicity against HER2+ breast cancer cells. Next-generation sequencing revealed PGB-0-ol modulates PI3K/Akt signaling and cell cycle pathways, offering potential for new HER2-targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies and monoclonal antibodies have improved outcomes for HER2+ breast cancer but drug resistance necessitates novel treatments.
  • A curcumin analog, PGB-0-ol, exhibits significant cytotoxicity against HCC1954 HER2+ breast cancer cells.

Purpose of the Study:

  • To elucidate the molecular mechanisms of PGB-0-ol action in HER2+ breast cancer cells using next-generation sequencing.
  • To identify key signaling pathways and biological processes affected by PGB-0-ol treatment.

Main Methods:

  • Next-generation sequencing (NGS) to analyze transcriptomic changes in HCC1954 cells treated with PGB-0-ol.
  • Bioinformatics analyses including Gene Ontology (GO), KEGG pathway, disease-gene, drug-gene associations, Network Topology Analysis (NTA), and Gene Set Enrichment Analysis (GSEA).

Main Results:

  • Identified 2,263 differentially expressed genes (DEGs) in PGB-0-ol-treated cells.
  • KEGG analysis indicated modulation of phosphatidylinositol and ErbB signaling pathways.
  • GO and GSEA revealed impacts on cell cycle, mitotic spindle, nuclear membrane, and kinase activity, specifically implicating PI3K/Akt signaling and cell cycle regulation.

Conclusions:

  • PGB-0-ol treatment alters the transcriptomic profile of HER2+ breast cancer cells.
  • Bioinformatics analyses suggest PGB-0-ol modulates PI3K/Akt signaling and cell cycle pathways.
  • Further research is needed to validate these findings and explore PGB-0-ol as a potential therapeutic agent.
Keywords:
AnticancerDrug developmentHER2+ breast cancerPGB-0-olTranscriptomics

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K